Dynamic Technology Lab Private Ltd Has $663,000 Holdings in LivaNova PLC $LIVN

Dynamic Technology Lab Private Ltd boosted its position in LivaNova PLC (NASDAQ:LIVN) by 8.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,869 shares of the company’s stock after buying an additional 1,286 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in LivaNova were worth $663,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UMB Bank n.a. grew its stake in LivaNova by 340.5% in the 1st quarter. UMB Bank n.a. now owns 837 shares of the company’s stock valued at $33,000 after buying an additional 647 shares during the last quarter. CWM LLC increased its holdings in shares of LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of LivaNova by 415.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock worth $58,000 after purchasing an additional 1,184 shares during the period. Central Pacific Bank Trust Division increased its holdings in shares of LivaNova by 7.0% during the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock worth $173,000 after purchasing an additional 290 shares during the period. Finally, Occudo Quantitative Strategies LP bought a new position in shares of LivaNova during the 4th quarter worth about $241,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Price Performance

Shares of LivaNova stock opened at $58.72 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The firm’s 50-day simple moving average is $49.20 and its 200-day simple moving average is $43.80. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $58.91. The firm has a market cap of $3.21 billion, a P/E ratio of -15.10 and a beta of 0.96.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. During the same period in the previous year, the business earned $0.93 EPS. The firm’s revenue was up 10.6% on a year-over-year basis. As a group, research analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on LIVN. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Barclays boosted their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a report on Tuesday, May 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.